ECT-001 Technology

ExCellThera’s lead solution, ECT-001, is based on the combination of two core technologies: a proprietary small molecule and an optimized culture system.

ECT-001 has several key advantages:

  • Excellent clinical outcomes
    • fast and persistent engraftment
    • faster immune reconstitution
    • low severe acute GvHD and no moderate to severe chronic GvHD
    • very low transplant-related mortality
  • Rapid and exponential expansion of stem and immune cells
  • Scalable, small-footprint, shorter lead time, low-cost production process
  • Cryo-preserved


ExCellThera Solution